← GIP/GLP-1 & amylin agonists × body weight & composition

TrialDiabetes, obesity & metabolism2025

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.

Emily R Hankosky et al.PubMed ↗Full text ↗Publisher ↗

Tirzepatide 10 mglooks bad hereNo clear link with weight reduction ≥5%.Correlation only, not a test of it.
Tirzepatide 15 mglooks bad hereHigher weight reduction ≥5%.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Tirzepatide 15 mg went with higher weight reduction ≥5%

1.8×1× to 3×

tirzepatide 15 mg vs semaglutide 2.4 mg

Bigger than 8 in 10 on the map

As reported

OR 1.76, 95% CI 1.04–2.97

Correlation · may be no link

No clear link with weight reduction ≥5%

1.2×0.8× to 2×

tirzepatide 10 mg vs semaglutide 2.4 mg

Bigger than 4 in 10 on the map

As reported

OR 1.24, 95% CI 0.75–2.04

+4 more in the walkthrough ↓

Who was studied, and how

people with type 2 diabetes, in this paper

Already taking tirzepatide 10 mg, or nottheir own situation, not assigned

on tirzepatide 10 mg

semaglutide 2.4 mg

Tirzepatide 10 mg went with higher percent weight reductions+2.57

No clear link with weight reduction ≥5%1.2×

Tirzepatide 10 mg went with higher HbA1c levels+0.47

correlation, not a test

Already taking tirzepatide 15 mg, or nottheir own situation, not assigned

on tirzepatide 15 mg

semaglutide 2.4 mg

Tirzepatide 15 mg went with higher percent weight reductions+4.79

Tirzepatide 15 mg went with higher weight reduction ≥5%1.8×

Tirzepatide 15 mg went with higher HbA1c levels+0.56

correlation, not a test

the abstract, start to end

… semaglutide (mean difference, 10 mg: 2.57%; 15 mg: 4.79%, p < 0.01).

… ≥5% weight reduction (odds ratio 15 mg: 1.76, 95% CI 1.04-2.97, p = 0.035; odds ratio 10 mg: 1.24, 95% CI 0.75-2.04, p = 0.407), and both tirzepatide doses were associated with significantly greater reductions in HbA1c (%) levels (mean difference, 10 mg: 0.47%; 15 mg: 0.56%, p < 0.001) than semaglutide.

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Mean percent weight reductionstirzepatide 10 mg vs semaglutide 2.4 mg

2.57

Mean percent weight reductionstirzepatide 15 mg vs semaglutide 2.4 mg

4.79

Weight reduction ≥5%tirzepatide 15 mg vs semaglutide 2.4 mg

OR 1.761.04–2.97

Weight reduction ≥5%tirzepatide 10 mg vs semaglutide 2.4 mg

OR 1.240.75–2.04

HbA1c (%) levelstirzepatide 10 mg vs semaglutide 2.4 mg

0.47

HbA1c (%) levelstirzepatide 15 mg vs semaglutide 2.4 mg

0.56

GIP/GLP-1 & amylin agonistsGlycemic controlBody weight & composition

1 / 4

4 papers cite it

2025

2026

this papertrialcites it

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.

What moved togetherboth groups pooled, not the treatment’s effect

Tirzepatide 15 mg went with higher weight reduction ≥5%

No clear link with weight reduction ≥5%

Who was studied, and how

Six numbers in the abstract

Where each one falls

Where it lands on the map

4 papers cite it